Sight Sciences (SGHT) to Release Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $16.51 million for the quarter. Sight Sciences has set its FY 2025 guidance at EPS.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The company had revenue of $19.07 million during the quarter, compared to analysts’ expectations of $18.98 million. During the same quarter in the previous year, the firm earned ($0.22) EPS. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Trading Up 7.1 %

Shares of SGHT stock opened at $3.20 on Thursday. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $164.32 million, a price-to-earnings ratio of -3.14 and a beta of 2.46. Sight Sciences has a 12-month low of $2.03 and a 12-month high of $8.45. The stock’s 50-day moving average price is $2.58 and its 200-day moving average price is $3.47.

Insider Activity

In other news, CEO Paul Badawi sold 24,174 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the transaction, the chief executive officer now directly owns 6,010,580 shares in the company, valued at approximately $13,824,334. This represents a 0.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Manohar K. Raheja acquired 10,000 shares of the stock in a transaction on Wednesday, March 12th. The stock was bought at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the transaction, the executive vice president now owns 145,000 shares in the company, valued at $395,850. This trade represents a 7.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 35,196 shares of company stock valued at $81,001. 28.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. UBS Group lowered their target price on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Monday, January 27th. Stifel Nicolaus reduced their target price on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Citigroup lowered their price target on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Wednesday, April 9th. Finally, Piper Sandler lowered their price objective on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.83.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.